Table 5: BMI comparison: Drug User Cohort to NHIS Data. (N=151).

 

BMI Classification

Underweight

Normal Weight

Overweight

Obese

Cohort

NHIS

Cohort

NHIS

Cohort

NHIS

Cohort

NHIS

Obs (% of 151)

Exp

Obs/Exp

p-value

95% CI

Obs (% of 151)

Exp

Obs/Exp

p-value

95% CI

Obs (% of 151)

Exp

Obs/Exp

p-value

95% CI

Obs (% of 151)

Exp

Obs/Exp

p-value

95% CI

 

Overall

7

(4.6)

1.76

3.98

0.005**

1.60-8.19

40 (26.5)

40.2

1.00

0.936

0.71-1.36

40 (26.5)

50.8

0.79

0.141

0.56-1.07

64 (42.4)

58.3

1.01

0.488

0.85-1.40

 

Hispanic

1

(0.7)

0.18

5.52

0.332

0.14-30.73

7

(4.6)

7.66

0.91

0.997

0.37-1.88

9

(6.0)

13.7

0.66

0.246

0.30-1.24

17 (11.3)

12.4

1.37

0.253

0.80-2.19

 

Black NH

4

(2.6)

0.54

7.36

0.005**

2.00-18.83

14

(9.3)

12.0

1.17

0.633

0.64-1.96

14 (9.3)

19.1

0.73

0.287

0.40-1.23

27 (17.9)

27.4

0.99

0.952

0.65-1.44

 

White NH

2

(1.3)

0.91

2.21

0.459

0.27-7.98

19 (12.6)

19.0

1.00

0.883

0.60-1.56

15 (9.9)

17.2

0.87

0.708

0.49-1.44

19 (12.6)

17.9

1.06

0.853

0.64-1.66

 

Male

3

(2.0)

0.39

7.69

0.015*

1.59-22.48

16 (10.6)

14.1

1.13

0.685

0.65-1.84

22 (14.6)

26.2

0.84

0.477

0.53-1.27

21 (13.9)

21.3

0.99

0.931

0.61-1.51

 

Female

4

(2.6)

1.37

2.92

0.101

0.80-7.48

24 (15.9)

26.0

 

0.92

0.786

0.59-1.37

18 (11.9)

24.6

0.73

0.213

0.43-1.16

43 (28.5)

37.0

1.16

0.365

0.84-1.57

 

21-35

1

(0.7)

0.52

1.91

0.814

0.05-10.66

9

(6.0)

9.49

0.95

0.955

0.43-1.80

4

(2.6)

6.34

0.63

0.484

0.17-1.62

9

(6.0)

6.64

1.35

0.452

0.62-2.57

 

36-40

1

(0.7)

0.15

6.65

0.279

0.17-37.07

4

(2.6)

4.69

0.85

1.000

0.23-2.19

5

(3.3)

6.90

0.72

0.627

0.24-1.69

8

(5.3)

6.26

1.28

0.586

0.55-2.52

 

41-45

1

(0.7)

0.13

7.78

0.241

0.20-43.33

4

(2.6)

3.39

1.18

0.878

0.32-3.02

2

(1.3)

4.01

0.50

0.472

0.06-1.80

5

(3.3)

4.47

1.12

0.924

0.36-2.61

 

46-50

N.C.

N.C.

N.C.

N.C.

N.C.

2

(1.3)

4.30

0.47

0.396

0.06-1.68

5

(3.3)

7.12

0.70

0.571

0.23-1.64

14 (9.3)

9.44

1.48

0.197

0.81-2.49

 

51-55

1

(0.7)

0.19

5.20

0.350

0.13-28.97

8

(5.3)

5.85

1.37

0.470

0.59-2.70

6

(4.0)

8.56

 

0.70

0.499

0.26-1.53

11 (7.3)

11.4

 

0.97

0.936

0.48-1.73

 

56-60

1

(0.7)

0.25

4.06

0.436

0.10-22.64

7

(4.6)

5.72

1.23

0.696

0.49-2.52

7

(4.6)

8.74

0.80

0.710

0.32-1.65

11 (7.3)

11.3

0.97

0.912

0.49-1.74

 

61-65

N.C.

N.C.

N.C.

N.C.

N.C.

4

(2.6)

4.34

0.92

0.874

0.25-2.36

7

(4.6)

5.66

1.24

0.679

0.50-2.55

5

(3.3)

5.76

0.87

1.000

0.28-2.02

 

66-85

2

(1.3)

0.14

13.91

0.019*

1.68-50.24

2

(1.3)

2.40

0.83

0.860

0.10-3.01

4

(2.6)

3.44

1.16

0.902

0.32-2.98

1

(0.7)

3.01

0.33

0.394

0.01-1.85

 

Younger Group

(Subjects ≤50)

3

(2.0)

0.94

3.18

0.140

0.66-9.30

19 (12.6)

21.9

0.87

0.633

0.52-1.36

16 (10.6)

24.4

0.66

0.097

0.38-1.07

36 (23.8)

26.8

1.34

0.104

0.94-1.86

 

Older Group

(Subjects >50)

4

(2.6)

0.82

4.89

0.020*

1.33-12.53

21 (13.9)

18.3

1.15

0.587

0.71-1.75

24 (15.9)

26.4113

 

0.91

0.731

0.58-1.35

28 (18.5)

31.5

0.89

0.611

0.59-1.29

 

PWID

5

(3.3)

1.15

4.37

0.013*

1.42-10.19

23 (15.2)

24.5

0.94

0.864

0.60-1.41

25 (16.6)

27.5

0.91

0.719

0.59-1.34

29 (19.2)

28.8

1.01

1.000

0.67-1.45

 

Non-PWID

2

(1.3)

0.61

3.27

0.252

0.40-11.80

17 (11.3)

15.7

1.09

0.800

0.63-1.74

15 (9.9)

23.3

0.65

0.094

0.36-1.06

35 (23.2)

29.5

1.19

0.353

0.83-1.65

 

Note: Standardized Prevalence Ratios were calculated to examine differences between drug user cohort and NHIS data. Boldface indicates statistical significance in two-tailed Fisher exact test (* p < 0.05 and ** p < 0.01).

PWID: Persons Who Inject Drugs; N.C.: Non-Calculable due to insufficient data; NH: Non-Hispanic.